How A 60-Year-Old Drug Developer Built A $4.4 Billion Biotech Treating ‘Butterfly Skin Disease’ https://t.co/saT86qKU93 https://t.co/FlooAn7uUU ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in three upcoming investor conferences taking place in September 2025. 2025 Wells Fargo Healthcare Conference Date:September 3, 2025Location:Boston, MAFormat:Inv ...

VANCOUVER, Washington, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York City. Robe ...

At $3.13 a share, I’m pretty bullish on Akebia (NASDAQ: AKBA ) stock. The 21% sell-off after Q2 earnings looks more like an overreaction than a red flag to me. Sure, the EPS quality wasn’t perfect, but the growthI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the ...

Core Viewpoint - NurExone Biologic Inc. reported its financial results for Q2 2025, highlighting advancements in its exosome-based therapies for central nervous system injuries and outlining its strategic plans for future clinical trials and manufacturing processes [1][4]. Financial Results - The company raised C$2.3 million through a private placement on April 10, 2025, selling 3,543,238 units at C$0.65 each, with proceeds aimed at working capital and clinical development [6]. - Research and development expenses for Q2 2025 were US$0.70 million, an increase from US$0.51 million in Q2 2024, attributed to higher service provider costs and stock-based compensation [6]. - General and administrative expenses rose to US$1.13 million in Q2 2025 from US$0.81 million in Q2 2024, driven by increased salaries and service provider costs [6]. - The net loss for Q2 2025 was US$1.85 million, compared to a loss of US$1.33 million in the same quarter of 2024 [6]. Corporate Highlights and Business Update - The company plans to initiate a Phase 1/2a trial of its lead product ExoPTEN for acute spinal cord injury in 2026, pending regulatory approvals [6]. - NurExone reported new manufacturing process validation data supporting the scalability and consistency of exosome production, with plans for tech transfer to its U.S. subsidiary Exo-Top for GMP manufacturing [6]. - The company was accepted into the Advanced Regenerative Manufacturing Institute's HealthTech Hub Accelerator to bolster its U.S. growth and manufacturing strategy [6][12]. - NurExone expanded its preclinical data set and engaged in scientific forums to enhance visibility and strategic partnerships [12]. Management Commentary - The CEO emphasized the importance of de-risking scale and quality through a validation-led manufacturing process and advancing U.S. tech transfer planning [7]. - The CFO noted that the April 2025 Offering strengthened the company's cash position to support ExoPTEN and align spending with milestone objectives [8]. About the Company - NurExone Biologic Inc. is focused on developing regenerative exosome-based therapies for central nervous system injuries, with its lead product ExoPTEN targeting acute spinal cord and optic nerve injuries, which represent multi-billion-dollar markets [9]. - The company has established Exo-Top Inc. as a U.S. subsidiary to anchor its North American activities and growth strategy [9].

Core Insights - IMUNON, Inc. has regained compliance with Nasdaq's minimum bid price requirement, ensuring uninterrupted trading on The Nasdaq Capital Market [1][2] - The company recently issued a 15% stock dividend to shareholders, reflecting confidence in its clinical pipeline and commitment to investors [2] - IMUNON's lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, with positive results from the Phase 2 OVATION 2 trial [2][4] Company Overview - IMUNON is a clinical-stage biotechnology company focused on innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases [3] - The company is developing non-viral DNA technology, with its first modality, TheraPlas, aimed at gene-based delivery of therapeutic proteins for solid tumors [3] - The second modality, PlaCCine, is designed for gene delivery of viral antigens to elicit strong immunological responses [3] Clinical Development - IMNN-001 instructs the body to produce cancer-fighting molecules at the tumor site and has completed multiple clinical trials, including the Phase 2 OVATION 2 trial [4] - IMUNON has also completed dosing in a first-in-human study of its COVID-19 booster vaccine, IMNN-101 [4] - The company aims to advance its technological capabilities in plasmid DNA to better address difficult-to-treat conditions [4]

SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has signed a Letter of Intent (the “LOI”) to potentially acquire Chemokine Pte Ltd (“Chemokine”). EUDA will carry out due diligence on Chemokine, subject to confidentiality obligations. Chemokine has agreed to an exclusivity period of at least one hundred and tw ...

Core Insights - Pasithea Therapeutics Corp. is participating in the H.C. Wainwright 27 Annual Global Investment Conference scheduled for September 8-10, 2025, in New York City [1][2] - The CEO, Dr. Tiago Reis Marques, will present the company and is available for one-on-one meetings during the event [2] - Pasithea is focused on developing PAS-004, a next-generation macrocyclic MEK inhibitor, currently in Phase 1 clinical trials for advanced cancer and neurofibromatosis type 1 [2] Company Overview - Pasithea Therapeutics is a clinical-stage biotechnology company dedicated to researching and developing PAS-004 for treating RASopathies, MAPK pathway-driven tumors, and other diseases [2] - PAS-004 is being tested in two clinical trials: a Phase 1 trial for advanced cancer patients (NCT06299839) and a Phase 1/1b trial for adult patients with NF1-associated plexiform neurofibromas (NCT06961565) [2]

How A 60-Year-Old Drug Developer Built A $4.4 Billion Biotech Treating ‘Butterfly Skin Disease’ https://t.co/qkR0ZbWuiG https://t.co/vvQdfOtlZA ...